Reprogramming enriches for somatic cell clones with small-scale mutations in cancer-associated genes.
Level 5 - mechanism / opinion, no new human data
Bench research analyzing human cell lines (CEBM Level 5).
PubMed 33831558 · doi:10.1016/j.ymthe.2021.04.007
What was done
Whole-exome sequencing was performed on 30 human induced pluripotent stem cell (hiPSC) lines. High-accuracy amplicon sequencing was used to trace identified small-scale variants back to parental somatic cell populations. A short hairpin RNA (shRNA) knockdown approach was applied to assess the impact of candidate genes on reprogramming efficiency.
What was found
All analyzed small-scale genetic variants pre-existed in parental cells rather than arising purely de novo. Mutations present in small subpopulations of parental cells became enriched among hiPSC clones during reprogramming. Enriched mutations affected genes governing cell-cycle control, cell death, and pluripotency. The abstract reports no numerical values, frequencies, or effect sizes.
Why it matters
This study shows reprogramming can act as a selective pressure that enriches rare oncogenic and tumor-suppressor mutations from parental cells. It highlights safety concerns and the need for genetic screening before using patient-derived hiPSCs in clinical cell therapies.
Limits
The analysis is restricted to in vitro bench research on 30 hiPSC lines. The abstract provides no exact numerical data, confidence intervals, or in vivo functional tumorigenicity testing.
Cited by
- supports When somatic cells are reprogrammed into induced pluripotent stem cells, somatic DNA mutations are retained and persist.